Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors

Not Applicable

Completed

Conditions: Liver Fibrosis
Non-alcoholic Fatty Liver Disease
Liver Injury

Interventions: Drug: Ganwei
Drug: Placebo
Drug: Metformin

First Posted Date: 2024-02-06

Last Posted Date: 2024-02-20

Lead Sponsor: Taipei City Hospital

Target Recruit Count: 60

Registration Number: NCT06244550

Locations: 🇨🇳
Taipei City Hospital, Taipei, Taiwan

Metformin Safety and Efficacy in Osteoarthritis.

Phase 3

Recruiting

Conditions: Osteo Arthritis Knee

Interventions: Drug: Celecoxib 200mg
Drug: Metformin

First Posted Date: 2024-01-30

Last Posted Date: 2024-02-02

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 70

Registration Number: NCT06231758

Locations: 🇪🇬
Mostafa Bahaa, Damietta, New Damietta, Egypt

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy Adults

Interventions: Drug: KP-001
Drug: Clarithromycin
Drug: Metformin
Drug: Midazolam

First Posted Date: 2024-01-29

Last Posted Date: 2024-03-27

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 38

Registration Number: NCT06227832

Locations: 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

Clinical and Biochemical Evaluation of 1% Metformin in Non-surgical Treatment of Periodontitis

Not Applicable

Completed

Conditions: Periodontitis

Interventions: Drug: Placebo
Drug: Metformin

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Ain Shams University

Target Recruit Count: 40

Registration Number: NCT06204185

Locations: 🇪🇬
Sameh Magdy Abou El-Kheir, Cairo, Egypt

Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome

Phase 1

Recruiting

Conditions: Comparative Study

Interventions: Drug: Metformin

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Hamdard University

Target Recruit Count: 150

Registration Number: NCT06199544

Locations: 🇵🇰
Shifa ul mulk memorial hospital, Karachi, Sindh, Pakistan

Metformin and Muscle Recovery

Early Phase 1

Recruiting

Conditions: Muscle Atrophy or Weakness

Interventions: Other: Placebo
Drug: Metformin

First Posted Date: 2023-12-29

Last Posted Date: 2024-11-11

Lead Sponsor: University of Utah

Target Recruit Count: 50

Registration Number: NCT06185179

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Metformin and Lactoferrin in Sepsis in Icu

Phase 2

Recruiting

Conditions: Sepsis

Interventions: Drug: Metformin
Drug: Lactoferrin

First Posted Date: 2023-12-26

Last Posted Date: 2024-04-19

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT06181422

Locations: 🇪🇬
Tanta, Tanta, Egypt

Insulin Sensitizers Role in Control of PCOS Vicious Cycle.

Phase 1

Completed

Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Interventions: Drug: Combination of Metformin hydrochloride and MI/DCI
Drug: Metformin Hydrochloride

First Posted Date: 2023-12-14

Last Posted Date: 2023-12-20

Lead Sponsor: Zagazig University

Target Recruit Count: 210

Registration Number: NCT06170463

Locations: 🇪🇬
Zagazig university, Zagazig, Ash Sharqia Governorate, Egypt

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Rosuvastatin
Drug: ALXN2080

First Posted Date: 2023-12-07

Last Posted Date: 2024-05-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT06160414

Locations: 🇬🇧
Research Site, Ruddington, United Kingdom

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Not Applicable

Not yet recruiting

Conditions: Decompensated Cirrhosis
Compensated Cirrhosis

Interventions: Drug: Metformin
Drug: Sitagliptin
Drug: Dapagliflozin

First Posted Date: 2023-11-27

Last Posted Date: 2023-12-08

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 240

Registration Number: NCT06147518

Locations: 🇮🇳
Dr Rakesh Kumar Jagdish, New Delhi, Delhi, India

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy